Conexeu Completes P.R.O.O.F Phase, Targets $11B Injectables Market
CNXU•Conexeu completed the P.R.O.O.F phase of its CXU preclinical program, validating facial, body and mechanical performance objectives for its tissue-restoration platform. The company targets an $11B injectables market and plans a predicate-based 510(k) filing in Q1 2027 to tap a $0.7B-$2B provider economy by 2030.
1. P.R.O.O.F Phase Completion
Conexeu completed its 12-month P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical study, meeting objectives across small-volume facial, large-volume body and mechanical performance evidence pillars and advancing CXU from concept to development stage.
2. Market Opportunity
The weight-loss drug sector reached $79B in 2025 and is projected at $190B by 2035, creating an $11B medical aesthetics injectables market with a provider economy expected to expand from $0.7B in 2025 to $2.0B by 2030.
3. Regulatory Pathway
Conexeu targets a predicate-based 510(k) submission for its first small-volume facial application in Q1 2027, leveraging the FDA's 90-day review process for faster market entry.
4. Competitive Landscape
Conexeu positions CXU as a structural extracellular matrix scaffold distinct from existing fillers and neuromodulators, aiming to compete against established players like AbbVie, Eli Lilly, Galderma Group and Novo Nordisk.
